The Trust is funding a Strategic Research Centre that aims to link the specific gut symptoms people with CF experience to what changes are taking place within their intestines. By increasing understanding of the cause of gut symptoms, the researchers hope that this could lead to more tailored medicines to treat people with CF in the future. The research is led by Professor Alan Smyth at University of Nottingham.
As 2025 comes to a close, we look back on a year of challenges and triumphs. From scientific breakthroughs to incredible fundraising challenges, here are some of the moments that defined our year.
Luke, 53, had a double lung transplant in 2019. His experience inspired him to write a memoir about his life with CF – and he now uses his voice to shape our work as a member of our Involvement Group.
Part 1 of study (now closed): HIT CF (Human Individualised Therapy in CF). Part 1 of the study (HIT CF) involved the collection of rectal biopsies from people with CF who have rare CFTR mutations and are not eligible for taking Kaftrio®. These rectal biopsies were used to grow organoids (aka ‘mini-organs’), and a new triple combination CFTR modulator therapy was tested for effectiveness on these organoids in a laboratory before assessing the medication directly in people with CF. This CFTR modulator therapy consists of dirocaftor (CFTR potentiator), posenacaftor (CFTR corrector) and nesolicaftor (CFTR amplifier), developed by FAIR Therapeutics –...
Find out how to apply for the Cystic Fibrosis Trust's Venture and Innovation Awards (VIAs) to help bring external funding to cystic fibrosis (CF) research.
